PGNX Financial Facts
Royalty income: 3.32MNet income (loss): 36.3M
See Full Income Statement
Total liabilities and stockholders' equity: 156.94M
Common stock: 91K
See Full Balance Sheet
Progenics Pharmaceuticals Inc. (PGNX) Earnings
|
Expand Research on PGNX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -0.6% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +9.0% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/8/18 |  |
Q417 | -$0.04 | N/A | N/A | $3.9M | $4.65M | = |  | | Details |
11/2/17  |
|
Q317 | N/A | -$0.23 | N/A | N/A | $3.52M | = | N/A | N/A | |
| 8/9/17 | Q217 | -$0.24 | -$0.21 | -$0.03 | $2.8M | $3.68M | = | | | Details | |
| 5/4/17 | |
Q117 | -$0.23 | -$0.19 | -$0.04 | $2.35M | $4.49M | = | | | Details |
| 3/9/17 | |
Q416 | -$0.10 | N/A | N/A | $4.65M | $5.1M | = | | | Details |
| 11/7/16 |
Q316 | $0.52 | $0.55 | -$0.03 | $53.9M | $52.9M | N/A | | | Details | |
| 8/4/16 |
|
Q216 | -$0.08 | -$0.13 | +$0.05 | $8.5M | $6.33M | N/A | | | Details |
| 5/5/16 |
Q116 | -$0.18 | -$0.13 | -$0.05 | $2.5M | $3.27M | N/A | | | Details |
